![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Cost-effectiveness analysis of a new paradigm to
simplify testing, monitoring and treatment of hepatitis C
virus in the United States
|
|
|
EASL 2023 June 21-24 Vienna
Douglas T. Dieterich1, Nancy S. Reau2, Aijaz Ahmed3, Rob Blissett4, Adam Igloi-Nagy4, Alon Yehoshua5. 1Institute for Liver Medicine, Mount Sinai Health System, United States; 2Rush University Medical Center, Department of Hepatology, Chicago, United States; 3Stanford University School of Medicine, Division of Gastroenterology and Hepatology, Stanford, United States; 4Maple Health Group, LLC,
New York, United States; 5Gilead Sciences, Inc, United States
![0625231](../images/062523/062523-17/0625231.gif)
![0625232](../images/062523/062523-17/0625232.gif)
![0625233](../images/062523/062523-17/0625233.gif)
![0625234](../images/062523/062523-17/0625234.gif)
![0625235](../images/062523/062523-17/0625235.gif)
![0625236](../images/062523/062523-17/0625236.gif)
![0625237](../images/062523/062523-17/0625237.gif)
![0625238](../images/062523/062523-17/0625238.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|